Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study.

Qian XiangZhe WangGuangyan MuQiufen XieZhiyan LiuShuang ZhouHanxu ZhangZining WangJie JiangKun HuYatong ZhangZinan ZhaoDongdong YuanLiping GuoTingting WuJinhua ZhangNa WangJing XiangZhichun GuJianjun SunYi Min Cui

Published in: Clinical and translational medicine (2023)

Peak anti-FXa level was associated with risk of bleeding events in patients with NVAF receiving rivaroxaban. SUSD3 rs76292544 was suggestively associated with 12-month bleeding events and five SNPs (NCMAP rs4553122, PRF1 rs885821, PRKAG2 rs12703159, rs13224758 and POU2F3 rs2298579) were suggestively associated with peak anti-FXa level.

Keyphrases

atrial fibrillation
oral anticoagulants
left atrial
catheter ablation
left atrial appendage
direct oral anticoagulants
venous thromboembolism
heart failure
percutaneous coronary intervention
genome wide
randomized controlled trial
pulmonary embolism
study protocol
dna methylation
mitral valve